Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Journey Medical Corp (DERM)

Journey Medical Corp (DERM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights GlobeNewswire - Tue Nov 12, 3:01PM CST

FBIO : 1.7200 (-1.15%)
DERM : 4.68 (+0.65%)
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea GlobeNewswire - Mon Nov 4, 6:00AM CST

FBIO : 1.7200 (-1.15%)
DERM : 4.68 (+0.65%)
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference GlobeNewswire - Fri Oct 25, 7:30AM CDT

FBIO : 1.7200 (-1.15%)
DERM : 4.68 (+0.65%)
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference GlobeNewswire - Thu Oct 3, 7:30AM CDT

FBIO : 1.7200 (-1.15%)
DERM : 4.68 (+0.65%)
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Globe Newswire - Tue Aug 9, 2022

Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021 DFD-29 Phase 3 studies 45% enrolled to date; 9 additional...

DERM : 4.68 (+0.65%)
FBIO : 1.7200 (-1.15%)
Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity Globe Newswire - Tue May 24, 2022

SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage...

FBIO : 1.7200 (-1.15%)
DERM : 4.68 (+0.65%)
Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference Globe Newswire - Mon May 23, 2022

SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical...

FBIO : 1.7200 (-1.15%)
DERM : 4.68 (+0.65%)
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022 AccessWire - Mon May 16, 2022

RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies...

ACST : 3.37 (-0.88%)
LPTH : 2.69 (+3.46%)
RCAT : 10.75 (+18.33%)
IONM : 0.0512 (+0.20%)
PYR : 0.3799 (unch)
OSS : 3.10 (+6.90%)
MODD : 1.3900 (-2.80%)
STRN : 1.3400 (+0.75%)
AEYE : 17.45 (+4.74%)
SMFL : 0.0100 (unch)
LFMD : 5.04 (+2.86%)
SURG : 1.7700 (+2.31%)
Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights Globe Newswire - Tue May 10, 2022

Generated record revenue of $23.3 million for the first quarter of 2022 First patient dosed in Phase 3 clinical program evaluating DFD-29 for the...

DERM : 4.68 (+0.65%)
FBIO : 1.7200 (-1.15%)
Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022 Globe Newswire - Tue May 3, 2022

Company to host conference call to discuss financial results and provide a corporate update on May 10, 2022 at 4:30 p.m. ET...

FBIO : 1.7200 (-1.15%)
DERM : 4.68 (+0.65%)

Barchart Exclusives

Why This Solar Stock Is a Tariff Winner to Buy for 2025 Barchart - 4 minutes ago
First Solar could be the "sole" beneficiary of new U.S. anti-dumping tariffs on countries like Vietnam and Malaysia. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot